about
Monogenic and polygenic determinants of sarcoma risk: an international genetic study.Treatment pathway of bone sarcoma in children, adolescents, and young adultsThe genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.Clinicopathologic features of a second patient with Ewing-like sarcoma harboring CIC-FOXO4 gene fusion.Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma.Synchronous indolent primary gastrointestinal lymphomas managed successfully with conservative measuresComprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis.Myoepithelial carcinoma with RB1 mutation: remarkable chemosensitivity to carcinoma of unknown origin therapy.Development and clinical application of an integrative genomic approach to personalized cancer therapyA phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome.Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers.Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma.MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation.The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation.Consensus and controversies regarding the treatment of rhabdomyosarcoma.Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue.Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors.Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic StudyIdentification of a novel MTAP-RAF1 fusion in a soft tissue sarcomaCombined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant MelanomaMultifocal primary neuroblastoma tumor heterogeneity in siblings with co-occurring PHOX2B and NF1 genetic aberrationsThe genetic script of metastasisThe genomic landscape of undifferentiated embryonal sarcoma of the liver is typified by C19MC structural rearrangement and overexpression combined with TP53 mutation or loss
P50
Q32491318-E2CE9762-99C4-4C5A-80A3-05DF83A25DB2Q33835657-38095BE8-7B91-4150-8126-AC8B75D1AD8CQ33881163-C2EA5B26-DCCB-401B-9819-56A5B0F3CD98Q34498569-F035031C-51F5-40DB-8A3E-0D06F7F0C417Q35345665-7B179FCA-9ED4-411B-98DF-6EBA45DB2D80Q35700213-80AC1107-11C4-4993-9C34-3025AD4978C6Q35711420-5D12F7FD-CFD2-4DF7-AE36-D4F13F47D1C8Q35739113-E2D9D006-6006-4A74-9DB0-6BFBC9E4D26DQ36340886-7B112E62-1A39-4B3E-8D9E-D433E3E55DACQ36954557-B47521DE-7D7D-48D8-84D8-4BBCDED180ADQ37518314-3588BF83-1A4D-4BAF-8F47-FFEB15B5B435Q37622856-8A9EAA21-AABA-41DE-B7D6-093718F137C9Q38591312-C794EAB0-D0BD-429A-9B38-93834FBF56B8Q38860405-AD41C65F-F7D8-40C8-9F32-36DF782EFDE7Q41139182-BC870ECC-6957-40F3-9AB6-76AF8AFEE551Q42385390-0876D283-1C08-48E2-A135-0999066B10EEQ43243489-4DD5152E-2F9F-4A93-80A3-EBE92B84CD80Q47123485-FDBC909C-6594-4FDB-8937-5BFB6B1D6E4FQ47687872-B701B0C2-5A3E-43D3-91DB-FD05B12EF488Q49627984-93071114-95D9-4B87-8C94-1E21D40520B1Q50089491-5A9105FE-BA6A-408E-9B0F-523922AD021EQ52649470-FD02CA46-6FCE-47B9-9A67-A1182188A100Q55282871-56FC0B50-6D6F-4190-8DD0-D03E67EB32B1Q57178496-8FDE6ED7-B5EF-4AC4-AECE-067812C53771Q57470803-E13271AB-4FFF-40B7-AF6C-F3EEBB786AB7Q58747510-5DE48856-544E-4874-82AD-9E0EC0E102ECQ90085168-4D3212FC-DC88-4A95-AEE7-9C52623157D6Q90995125-F86EE94A-B2A8-45B6-9523-8808C0D4ABC3Q92078072-36A083AB-E45B-4ABE-ACE0-770AE427F463
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Andrew S Brohl
@ast
Andrew S Brohl
@en
Andrew S Brohl
@es
Andrew S Brohl
@nl
type
label
Andrew S Brohl
@ast
Andrew S Brohl
@en
Andrew S Brohl
@es
Andrew S Brohl
@nl
prefLabel
Andrew S Brohl
@ast
Andrew S Brohl
@en
Andrew S Brohl
@es
Andrew S Brohl
@nl
P106
P31
P496
0000-0002-0071-0534